SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- DNA repair in cancer initiation, progression, and therapy-a double-edged sword.Journal of applied genetics · 2019Review
- Common polymorphisms of theBioscience reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several case-control studies on the relation between XRCC1 gene Arg399Gln polymorphism and laryngeal cancer do not have similar conclusions. To further evaluate the relation between the XRCC1 gene Arg399Gln polymorphism and laryngeal cancer, we selected seven case-control studies related to the XRCC1 gene Arg399Gln polymorphism and laryngeal cancer by searching MEDLINE, EMBase, Chinese Biomedical Literature Database, Chinese CNKI, and Wanfang database. We utilized Q test and I (2) test to test the heterogeneity between each study. The fixed effects model was utilized to calculate the odds ratio (OR) and 95 % confidence interval. The present study included 1,654 patients with laryngeal cancer and 2,377 cancer-free control subjects. By meta-analysis, we did not find any association of XRCC1 gene Arg399Gln polymorphism with laryngeal cancer (OR = 1.13, 95 % CI 0.81-1.58, P = 0.47). Therefore, we concluded that XRCC1 gene Arg399Gln polymorphism was not associated with laryngeal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.